Drugs / autologous PBMCs
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00324623 | Sep 2005 → Nov 2011 | cutaneous melanoma | Prof. Serge Leyvraz | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00204594 | Oct 2005 → Dec 2007 | melanoma | University Hospital Tuebingen | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT01875653 Comparator | Oct 2014 → Jan 2016 | melanoma | Lisata Therapeutics, Inc. | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | autologous PBMCs | “lymphodepleting chemotherapy and adoptive transfer of autologous PBMCs at day (D) 0” PMID 24726012 ↗ Apr 2014 |
| Modality | Cell therapy | “autologous PBMCs” NCT00204594 ↗ |
| Route | Other | “intralesional application of the bispecific single chain antibody rM28 and autologous PBMCs” NCT00204594 ↗ |